{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:53:26Z","timestamp":1779292406551,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clon.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T17:13:43Z","timestamp":1635614023000},"page":"e61-e68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of Baseline Patient-reported Health-related Quality of Life Metrics with Outcome in Localised Prostate Cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"S.","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2021.10.007_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib2","first-page":"1267","article-title":"Predicting survival in prostate cancer: the role of quality of life assessment","volume":"20","author":"Braun","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clon.2021.10.007_bib3","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","article-title":"Pain predicts overall survival in men with metastatic castration-refractory prostate cancer","volume":"26","author":"Halabi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11136-006-0003-2","article-title":"Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer","volume":"15","author":"Sullivan","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clon.2021.10.007_bib5","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2004.07.089","article-title":"Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group","volume":"22","author":"Collette","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.09.035","article-title":"The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies","volume":"87","author":"Beer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2021.10.007_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.19.01904","article-title":"Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial","volume":"38","author":"Malone","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ijrobp.2021.01.032","article-title":"Patient-reported outcomes from a phase III randomized controlled trial exploring optimal sequencing of short-term androgen deprivation therapy with prostate radiotherapy in localized prostate cancer","volume":"110","author":"Roy","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.10.007_bib9","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1016\/j.prro.2020.09.013","article-title":"Impact of treating physician on radiotherapy related severe toxicities in men with prostate cancer","volume":"11","author":"Roy","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib10","series-title":"A\u00a0language and environment for statistical computing","year":"2019"},{"key":"10.1016\/j.clon.2021.10.007_bib11","unstructured":"Therneau TM. Survival analysis [R package survival version 3.1-11]."},{"key":"10.1016\/j.clon.2021.10.007_bib12","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/annonc\/mdw433","article-title":"The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy","volume":"27","author":"Perrone","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib13","first-page":"153","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2021.10.007_bib14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2021.10.007_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.pcan.4500975","article-title":"Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer","volume":"10","author":"Galv\u00e3o","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clon.2021.10.007_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jjco\/hyy101","article-title":"Lifestyle interventions to alleviate side effects on prostate cancer patients receiving androgen deprivation therapy: a meta-Analysis","volume":"48","author":"Ying","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clon.2021.10.007_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.annepidem.2009.08.003","article-title":"Financial hardship and mortality among older adults using the 1996-2004 Health and Retirement Study","volume":"19","author":"Tucker-Seeley","year":"2009","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.clon.2021.10.007_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PSY.0000000000000276","article-title":"The psychosocial context of financial stress: implications for inflammation and psychological health","volume":"78","author":"Sturgeon","year":"2016","journal-title":"Psychosom Med"},{"key":"10.1016\/j.clon.2021.10.007_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.21037\/apm.2018.06.09","article-title":"Predictors of dyspnea in patients with advanced cancer","volume":"7","author":"McKenzie","year":"2018","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.clon.2021.10.007_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/107327481502200415","article-title":"Prognostication of survival in patients with advanced cancer: predicting the unpredictable?","volume":"22","author":"Hui","year":"2015","journal-title":"Cancer Control"},{"key":"10.1016\/j.clon.2021.10.007_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2490-13-32","article-title":"Prognostic value of changes in quality of life scores in prostate cancer","volume":"13","author":"Gupta","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.clon.2021.10.007_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2021.10.007_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.trecan.2016.05.006","article-title":"Hypoxia: signaling the metastatic cascade","volume":"2","author":"Rankin","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.clon.2021.10.007_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1615\/CritRevOncog.v20.i5-6.130","article-title":"Hypoxia-induced signaling promotes prostate cancer progression: exosomes role as messenger of hypoxic response in tumor microenvironment","volume":"20","author":"Deep","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.clon.2021.10.007_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"10.1016\/j.clon.2021.10.007_bib27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cyto.2011.08.029","article-title":"Systemic inflammation and cell activation reflects morbidity in chronic heart failure","volume":"56","author":"Dixon","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.clon.2021.10.007_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/SPC.0000000000000229","article-title":"Breathlessness and inflammation: potential relationships and implications","volume":"10","author":"Ryan","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clon.2021.10.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.00442","article-title":"Dyspnea and exercise limitation in mild COPD: the value of CPET","volume":"7","author":"James","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.clon.2021.10.007_bib30","first-page":"549","article-title":"Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer","volume":"31","author":"Langenhuijsen","year":"2013","journal-title":"Urol Oncol Semin Orig Investig"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521003733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521003733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:49:43Z","timestamp":1760543383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655521003733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0936655521003733"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2021.10.007","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Baseline Patient-reported Health-related Quality of Life Metrics with Outcome in Localised Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}